Skip to content
Screener
Q3 '26Q2 '26Q1 '26Q4 '25Q3 '25
$3.06M+111%-$43.4M-253%-$44.5M-195%-$46.14M—-$27.08M-13.5%
$2.14M+2.3%$1.91M-10.1%$2.03M-0.9%$2.09M+1.3%$2.1M-0.4%
$6.32M+44.9%$5.97M+22.0%$5.95M+12.3%$4.31M-3.6%$4.36M+1.9%
-$40.98M-141%-$44.11M-27.1%-$37.37M+17.9%-$43.01M-133%$100.43M+578%
$1.56M+139%$4.72M+179%$1.87M+17.7%$767K+319%$651K+63.2%
-$4.54M—-$28.86M—-$261M-160%-$65.07M-111%——
$568K+63.2%$3.21M+780%$328.34M+2,345,150%$29.62M+4,772%$348K+2,220%
-$44.95M—-$69.76M-672%$29.97M+121%-$78.46M-180%——
-$42.54M-143%-$48.84M-34.1%-$39.24M+16.7%-$43.78M-134%$99.78M+566%

FAQ

How much cash does Monte Rosa Therapeutics, Inc. generate?
Monte Rosa Therapeutics, Inc. (GLUE) generated -$165.5M in operating cash flow over the trailing twelve months.
What is Monte Rosa Therapeutics, Inc.'s free cash flow?
After $8.9M of capital expenditures, Monte Rosa Therapeutics, Inc.'s free cash flow was -$174.4M over the trailing twelve months, down 220.3% year over year.
Where does Monte Rosa Therapeutics, Inc.'s cash flow data come from?
Every line is extracted from Monte Rosa Therapeutics, Inc.'s SEC filings (10-K and 10-Q) and tagged in XBRL. Switch between quarterly, annual, and trailing-twelve-month views, or open any line for its full history and peer comparisons.